KAKristina A. Arakelyan

Kristina A. Arakelyan

*This is an algorithmically generated author record based on publicly available information.

Kristina A. Arakelyan has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correlation features of oral mucosits and psychological status in patients with squamous cell carcinoma of the oral mucosa at the stage of chemoradiation therapy

    by A. A. Dzhereley, I. G. Romanenko, К. A. Arakelyan, D. Y. Kryuchkov, S. М. Gorobets, S. A. Bobkova, Д. Ю. Крючков

    Mucosits of the oral mucosa as a complication of cancer treatment remains an urgent problem. The risk of developing mucosits is classically directly related to the type, intensity of anticancer treatment, and type of psychological response. Combination therapy increases the severity of mucosits. The frequency of mucosits 3–4 degrees according to the WHO scale reaches 85 % and is considered severe among patients receiving high-dose radiation therapy to the head and neck area. In squamous cell carcinoma of the oral mucosa, oral mucosits is the main limiting factor in chemo radiation therapy.It is often necessary to resort to enteral nutritional support and the use of morphine-type analgesics to complete the planned exposure, or to interrupt therapy. In order to prevent mucosits, we studied the correlation between its degree and psychological reactions. The studied psychosomatic status of patients with squamous cell carcinoma of oral mucosa, who are at the stage of chemoradiation therapy, complicated by mucosits, showed a direct relationship between these indicators.


  • Possibilities Of Correcting Iatrogenic Mucositis With Cyanides In Experiment

    by Kristina A. Arakelyan, Inessa G. Romanenko, Elena P. Golubinskaya, Evgeniya Yu. Zyablitskaya, Tatyana P. Makalish

    Background — Radiation and chemotherapy of cancer cause complications that drastically reduce the quality of life. This requires the search for effective therapeutic agents for the mucositis treatment. We investigated the effects of amygdalin as a trophic external agent for post-radiation and post-chemotherapeutic oral mucositides. The study objectives were to conduct an immunomorphological analysis using an experimental model of iatrogenic mucositis, and to evaluate the effectiveness of amygdalin as cyanide with probable protective chemical properties in mucositis correction. Material and Methods — Our studies were performed on 40 male white rats. Radiation therapy was simulated by irradiating animals with a cranial dose of 6 Gy. Then an intraperitoneal injection of cisplatin was performed. On day 7, a biopsy was taken (model control), and animals were treated for 14 days with a mixture of 0.02% nitrofurazone, Desensitin® gel, Suprasorb® and amygdalin, after which a biopsy was taken again (therapy control). Results — Immunomorphological studies revealed dystrophic structural changes due to the progress of tissue hypoxia and the launch of Fas-dependent apoptosis in tissues. Using treatment with amygdalin by activating hypoxia-inducible factor (HIF) stimulates the macrophage population to remodel the stroma of the submucosal layer. In addition to activating the cellular components of local immunity, a therapeutic anti-apoptotic effect has been established. Conclusion — The method of mucositis correction by amygdalin is effective, which is confirmed by increased proliferation and decreased apoptosis due to revascularization and hypoxia reduction.